Lynn M D, Shapiro B, Sisson J C, Swanson D P, Mangner T J, Wieland D M, Meyers L J, Glowniak J V, Beierwaltes W H
J Nucl Med. 1984 Apr;25(4):436-40.
The radiopharmaceutical m-[131I]iodobenzylguanidine (I-131 MIBG), which is readily taken up by adrenergic vesicles, produces scintigraphic images of pheochromocytomas in man but rarely visualizes normal adrenal glands. Iodine-123 has many potential advantages over I-131 as a radiolabel for MIBG, including shorter half-life, freedom from beta emissions, and increased gamma-camera efficiency. In this study, diagnostic doses of MIBG labeled with I-131 and I-123, with nearly equivalent radiation dosimetry, were compared as imaging agents in eight patients with known or suspected pheochromocytoma. Images of superior quality were obtained with I-123 MIBG, and lesions not visualized using I-131 MIBG were portrayed. In addition, the normal adrenal medullae were visualized on the I-123 MIBG scintigrams in six out of eight patients.
放射性药物间位[¹³¹I]碘苄胍(I-131 MIBG)很容易被肾上腺素能囊泡摄取,可生成人体嗜铬细胞瘤的闪烁显像图,但很少能显示出正常肾上腺。与¹³¹I相比,碘-123作为MIBG的放射性标记物有许多潜在优势,包括半衰期较短、无β射线发射以及γ相机效率提高。在本研究中,将标记有¹³¹I和¹²³I且辐射剂量测定几乎相同的诊断剂量MIBG作为显像剂,在8例已知或疑似嗜铬细胞瘤患者中进行比较。使用¹²³I MIBG获得了高质量图像,描绘出了使用¹³¹I MIBG未能显示的病变。此外,8例患者中有6例在¹²³I MIBG闪烁显像图上显示出了正常肾上腺髓质。